CN104619724B - 识别α-突触核蛋白的人源化抗体 - Google Patents

识别α-突触核蛋白的人源化抗体 Download PDF

Info

Publication number
CN104619724B
CN104619724B CN201380007018.8A CN201380007018A CN104619724B CN 104619724 B CN104619724 B CN 104619724B CN 201380007018 A CN201380007018 A CN 201380007018A CN 104619724 B CN104619724 B CN 104619724B
Authority
CN
China
Prior art keywords
antibody
seq
occupied
heavy chain
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201380007018.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN104619724A (zh
Inventor
约瑟·萨尔丹哈
塔洛陈·S.·尼扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prothena Biosciences Ltd
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Priority to CN201810297949.0A priority Critical patent/CN108517010A/zh
Publication of CN104619724A publication Critical patent/CN104619724A/zh
Application granted granted Critical
Publication of CN104619724B publication Critical patent/CN104619724B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201380007018.8A 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体 Expired - Fee Related CN104619724B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810297949.0A CN108517010A (zh) 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261591835P 2012-01-27 2012-01-27
US61/591,835 2012-01-27
US201261711207P 2012-10-08 2012-10-08
US61/711,207 2012-10-08
PCT/US2013/023307 WO2013112945A1 (en) 2012-01-27 2013-01-25 Humanized antibodies that recognize alpha-synuclein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810297949.0A Division CN108517010A (zh) 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体

Publications (2)

Publication Number Publication Date
CN104619724A CN104619724A (zh) 2015-05-13
CN104619724B true CN104619724B (zh) 2018-05-04

Family

ID=48873980

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380007018.8A Expired - Fee Related CN104619724B (zh) 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体
CN201810297949.0A Pending CN108517010A (zh) 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810297949.0A Pending CN108517010A (zh) 2012-01-27 2013-01-25 识别α-突触核蛋白的人源化抗体

Country Status (22)

Country Link
US (7) US8790644B2 (enExample)
EP (1) EP2807188B1 (enExample)
JP (2) JP6342333B2 (enExample)
KR (2) KR102246217B1 (enExample)
CN (2) CN104619724B (enExample)
AU (1) AU2013211874B2 (enExample)
BR (1) BR112014018561A8 (enExample)
CA (1) CA2863953A1 (enExample)
CL (1) CL2014001984A1 (enExample)
DK (1) DK2807188T3 (enExample)
ES (1) ES2749457T3 (enExample)
IL (2) IL233829B (enExample)
IN (1) IN2014DN07149A (enExample)
MX (2) MX360778B (enExample)
MY (1) MY171140A (enExample)
NZ (1) NZ629296A (enExample)
PH (1) PH12014501685A1 (enExample)
RU (1) RU2642262C2 (enExample)
SG (1) SG11201404321YA (enExample)
UA (1) UA115439C2 (enExample)
WO (1) WO2013112945A1 (enExample)
ZA (1) ZA201406227B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014010198B1 (pt) 2011-10-28 2022-12-06 Prothena Biosciences Limited Anticorpos humanizados que reconhecem alfa-sinucleína
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
NZ715896A (en) * 2013-07-05 2022-02-25 Genmab As Humanized or chimeric cd3 antibodies
SI3071597T1 (sl) * 2013-11-21 2020-11-30 F. Hoffmann-La Roche Ag Anti alfa-sinukleinska protitelesa in postopki uporabe
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
CN107074938A (zh) 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
CN106568969B (zh) * 2016-10-19 2017-09-26 首都医科大学 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法
CA3042302A1 (en) * 2016-12-02 2018-06-07 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
EA039807B1 (ru) 2017-01-06 2022-03-16 ЭйБиЭл БИО ИНК. Антитело к -синуклеину и его применение
EP3583124A1 (en) * 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
US11098108B2 (en) * 2017-08-02 2021-08-24 Stressmarq Biosciences Inc. Antibody binding active alpha-synuclein
CN116731173A (zh) * 2017-12-14 2023-09-12 Abl生物公司 抗a-syn/igf1r的双特异性抗体及其用途
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
EP3773718A4 (en) 2018-04-06 2022-01-19 aTyr Pharma, Inc. COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES
WO2020033756A1 (en) 2018-08-09 2020-02-13 F. Hoffmann-La Roche Ag Determination of parkinson's disease
BR112021006123A2 (pt) * 2018-10-19 2021-07-20 Janssen Vaccines & Prevention B.V. anticorpos anti-sinucleína
EP4037711A4 (en) * 2019-10-03 2024-02-14 Atyr Pharma, Inc. COMPOSITIONS AND METHODS USING ANTI-NRP2 ANTIBODIES
CR20220531A (es) 2020-04-24 2022-11-28 Hoffmann La Roche Modulacion de enzimas y vías con compuestos de sulfhidrilo y sus derivados
MX2023000949A (es) * 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
TW202309076A (zh) * 2021-05-12 2023-03-01 南韓商Ａｂｌ生物公司 用於治療α-突觸核蛋白病之抗體
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039234A2 (en) * 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
DE69620877T2 (de) 1995-02-06 2002-12-12 Genetics Institute, Inc. Arzneimittelformulierungen für il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ATE371231T1 (de) 1999-02-05 2007-09-15 Samsung Electronics Co Ltd Verfahren und vorrichtung zur wiederauffindung von texturbildern
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US7657380B2 (en) * 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DK1567652T3 (da) 2002-11-29 2007-11-26 Boehringer Ingelheim Pharma Nye neomycin-phosphotransferasegener og fremgangsmåde til selektion af höjtproducerende rekombinante celler
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) * 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US7930064B2 (en) * 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
CA2657953A1 (en) 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
DK2099826T3 (da) * 2007-01-05 2014-01-20 Univ Zuerich Anti-beta-amyloid-antistof og anvendelser deraf
CN101663320A (zh) 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
JP5558834B2 (ja) * 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
SG182160A1 (en) 2007-03-02 2012-07-30 Boehringer Ingelheim Pharma Improvement of protein production
BRPI0809112A2 (pt) 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
RS53402B (sr) 2007-03-22 2014-10-31 Genentech, Inc. Vezivanje apoptotskih anti-ige antitela za membranski ige
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
AU2008340429C1 (en) 2007-12-21 2016-09-08 F. Hoffmann-La Roche Ag Antibody formulation
CN102016059B (zh) 2007-12-28 2014-10-22 依兰制药公司 淀粉样变性的治疗和预防
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
LT2282758T (lt) 2008-04-29 2019-03-12 Bioarctic Ab Antikūnai ir vakcinos, skirti su alfa sinukleinu susijusių sutrikimų gydymo ir diagnostiniams metodams
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
NZ598156A (en) 2009-07-28 2014-06-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
WO2011127324A2 (en) * 2010-04-08 2011-10-13 JN Biosciences, LLC Antibodies to cd122
CA2799540A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
CA2805112A1 (en) * 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
MX344268B (es) 2010-10-11 2016-12-09 Abbvie Inc * Proceso para purificacion de proteinas.
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
WO2012177997A1 (en) 2011-06-22 2012-12-27 The General Hospital Corporation Treatment of proteinopathies
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
BR112014010198B1 (pt) 2011-10-28 2022-12-06 Prothena Biosciences Limited Anticorpos humanizados que reconhecem alfa-sinucleína
RS63948B1 (sr) 2011-10-31 2023-02-28 Hoffmann La Roche Formulacije anti-il13 antitela
DK2807188T3 (da) * 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
KR20150039798A (ko) 2012-08-29 2015-04-13 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039234A2 (en) * 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Affinity Maturation of a Humanized Rat Antibody for Anti-RAGE Therapy: Comprehensive Mutagenesis Reveals a High Level of Mutational Plasticity Both Inside and Outside the Complementarity-Determining Regions;William J. Finlay et al.;《Journal of Molecular Biology》;20090508;第388卷(第3期);第541-558页 *

Also Published As

Publication number Publication date
WO2013112945A1 (en) 2013-08-01
IL281731A (en) 2021-05-31
EP2807188A1 (en) 2014-12-03
AU2013211874B2 (en) 2017-11-02
NZ629296A (en) 2016-06-24
US10118960B2 (en) 2018-11-06
US20130266517A1 (en) 2013-10-10
US20160251416A1 (en) 2016-09-01
JP6342333B2 (ja) 2018-06-13
MY171140A (en) 2019-09-27
BR112014018561A8 (pt) 2017-07-11
IL233829A0 (en) 2014-09-30
KR20140125409A (ko) 2014-10-28
KR102086061B1 (ko) 2020-03-11
UA115439C2 (uk) 2017-11-10
SG11201404321YA (en) 2014-08-28
MX2018014044A (es) 2021-12-08
US9670273B2 (en) 2017-06-06
US20190153080A1 (en) 2019-05-23
ZA201406227B (en) 2016-02-24
RU2014134747A (ru) 2016-03-20
HK1204791A1 (en) 2015-12-04
US20150024433A1 (en) 2015-01-22
KR102246217B1 (ko) 2021-04-29
MX360778B (es) 2018-11-16
US10875909B2 (en) 2020-12-29
MX2014008952A (es) 2015-02-20
IN2014DN07149A (enExample) 2015-04-24
RU2642262C2 (ru) 2018-01-24
DK2807188T3 (da) 2019-10-07
AU2013211874A1 (en) 2014-09-18
KR20200027570A (ko) 2020-03-12
ES2749457T3 (es) 2020-03-20
JP2018148911A (ja) 2018-09-27
CN104619724A (zh) 2015-05-13
US9234031B2 (en) 2016-01-12
CN108517010A (zh) 2018-09-11
PH12014501685A1 (en) 2014-11-10
US20180016329A1 (en) 2018-01-18
JP6807893B2 (ja) 2021-01-06
CA2863953A1 (en) 2013-08-01
IL233829B (en) 2021-04-29
BR112014018561A2 (enExample) 2017-06-20
US20150056187A1 (en) 2015-02-26
EP2807188A4 (en) 2015-07-01
US10597441B2 (en) 2020-03-24
US8790644B2 (en) 2014-07-29
US20200277362A1 (en) 2020-09-03
US9217030B2 (en) 2015-12-22
JP2015508062A (ja) 2015-03-16
EP2807188B1 (en) 2019-09-11
CL2014001984A1 (es) 2014-12-19

Similar Documents

Publication Publication Date Title
CN104619724B (zh) 识别α-突触核蛋白的人源化抗体
CN104334184B (zh) 识别α‑突触核蛋白的人源化抗体
CN104822389B (zh) 识别α-突触核蛋白的抗体
RU2575629C2 (ru) Гуманизированные антитела, которые распознают альфа-синуклеин
HK1260936A1 (en) Humanized antibodies that recognize alpha-synuclein
HK1261629A1 (en) Humanized antibodies that recognize alpha-synuclein
HK1204791B (en) Humanized antibodies that recognize alpha-synuclein

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: North wall pier 25-28, Dublin, Ireland

Applicant after: NEOTOPE BIOSCIENCES LTD.

Address before: North wall pier 25-28, Dublin, Ireland

Applicant before: NEOTOPE BIOSCIENCES Ltd.

COR Change of bibliographic data
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180504

Termination date: 20220125